Gallbladder disease : GLP-1 receptor agonists may increase the risk of gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis)
Besides, there has been an increase in the occurrence from 30.5% in previous years and 4.7% surge in severe obesity, thereby making it suitable for enhancing the semaglutide market growth in the region
Its usability is hampered by stress, alcohol, tobacco, viral diseases, antibiotics, painkillers, exposure to carbon monoxide, heavy metals and other pollutants
Therefore, in this study, it is believed that EX-4 might also affect the -cell viability, which might contribute to the increase of serum GLP-1